Startseite > Publikationen
Phase-III-Studien
Daten aus den HAWK- und HARRIER-Studien, Woche 96
Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, et al. HAWK and HARRIER: 96-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-related Macular Degeneration. Ophthalmologie 2020; im Druck.
Daten aus den HAWK- und HARRIER-Studien, Woche 48
Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmologie 2020; 127: 72–84.
Phase-II-Studien
Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, et al. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology 2017; 124: 1296–304.
Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, et al. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study. Ophthalmology 2016; 123: 1080–9.
Berichte des Komitees zur Bewertung von Sicherheitsdaten
Komitee zur Bewertung von Sicherheitsdaten (SRC). Novartis-Appointed Safety Review Committee Reports Initial Brolucizumab Findings. Veröffentlicht Juni 2020
Post-hoc Analyse HAWK and HARRIER
Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, et al.: Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER. Ophthalmology 2020; im Druck